

**BEST AVAILABLE COPY**

Appl. No. 10/007,459  
Amdt. dated 11/2/2006  
Reply to Notice of October 26, 2006

RECEIVED  
CENTRAL FAX CENTER  
NOV 02 2006

**AMENDMENTS TO THE CLAIMS**

In the claims, please amend claims 11, 14, and 18 as follows:

1-10. (canceled)

11. (currently amended) A process for inhibiting expression of a gene in a parenchymal cell in a target tissue in a mammal, comprising:

- a) mixing a double strand RNA oligonucleotide consisting of a sequence that is substantially complementary a portion of a sequence of the gene and a compound selected from the group consisting of amphipathic compounds, polymers and non-viral vectors to form a complex wherein the zeta potential of the complex is less negative than the zeta potential of the double strand RNA oligonucleotide alone;
- b) inserting the complex into an efferent or afferent mammalian vessel of the target tissue in vivo thereby increasing permeability of vessels within the target tissue and delivering the double strand RNA oligonucleotide to the parenchymal cell, wherein the double strand RNA oligonucleotide inhibits expression of the gene.

12. (canceled)

13. (previously presented) The process of claim 11 wherein increasing the permeability of the vessel consists of increasing pressure against vessel walls.

14. (currently amended) The process of claim 13 wherein the parenchymal cell is selected from the group consisting of liver cells, spleen cells, heart cells, kidney cells, prostate cells, skin cells, testis cells, skeletal muscle cells, fat, bladder cells, brain cells, pancreas cells, thymus cells, and lung cells.

15. (previously presented) The process of claim 11 wherein the complex has a positive charge.

16. (previously presented) The process of claim 11 wherein the complex has a negative charge.

17. (previously presented) The process of claim 13 wherein increasing the pressure consists of increasing volume of fluid within the vessel.

18. (currently amended) The process of claim 17 wherein the fluid solution is inserted within 2 minutes.

**BEST AVAILABLE COPY**


Appl. No. 10/007,459

Amdt. dated 11/2/2006

Reply to Notice of October 26, 2006

If there are any questions or concerns, please contact the undersigned.

Respectfully submitted,



Kirk Ekena, Reg. No. 56,672  
Mirus Bio Corporation  
505 South Rosa Road  
Madison, WI 53719  
608-238-4400

I hereby certify that this correspondence is being facsimile  
transmitted to the USPTO or deposited with the United  
States Postal Service with sufficient postage as express  
mail in an envelope addressed to: Commissioner for  
Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on  
this date: November 2, 2006.

  
Kirk Ekena/  
Kirk Ekena